| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w28866 |
| 来源ID | Working Paper 28866 |
| Common Agent or Double Agent? Pharmacy Benefit Managers in the Prescription Drug Market | |
| Rena M. Conti; Brigham Frandsen; Michael L. Powell; James B. Rebitzer | |
| 发表日期 | 2021-05-31 |
| 出版年 | 2021 |
| 语种 | 英语 |
| 摘要 | A small number of pharmacy benefit managers (PBMs) dominate the market for branded pharmaceuticals in the United States, but they are controversial, and their economic significance is poorly understood. Large PBMs are market intermediaries. They are also a common agent operating formularies on behalf of various third-party payers. We present a model that captures these dual roles and also clarifies the economics of drug rebates. We find that PBM-run formularies enhance the efficiency of drug markets, but when PBMs are highly concentrated these gains accrue to PBMs rather than consumers or drug makers. We also identify threats to formulary efficiency including most favored nation agreements between drug makers and PBMs and the strategic setting of high list prices by drug makers. Our model also offers insights into current market structures and a framework for assessing market reforms. |
| 主题 | Health, Education, and Welfare ; Health ; Industrial Organization ; Market Structure and Firm Performance |
| URL | https://www.nber.org/papers/w28866 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/586540 |
| 推荐引用方式 GB/T 7714 | Rena M. Conti,Brigham Frandsen,Michael L. Powell,et al. Common Agent or Double Agent? Pharmacy Benefit Managers in the Prescription Drug Market. 2021. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w28866.pdf（801KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
